Homocysteine

Homocysteine is one of the more useful numbers on a panel, and also one of the most misunderstood. It is best known as a cardiovascular risk factor, and it genuinely tracks with heart attack, stroke, and cognitive decline. But the story of what to do about it took a surprising turn, and getting that turn right is the difference between using this marker well and chasing it pointlessly.

At its simplest, homocysteine is a waste product of the body's methylation machinery, and it is supposed to be cleared continuously by a small set of B vitamins. Without enough of them, it backs up in the blood. So more than anything, a high homocysteine is a sensitive early sign that your folate, B12, or B6 status is inadequate, often before any other test would show it.

That dual identity, part B-vitamin gauge and part vascular risk marker, is what makes it worth measuring. The catch, which the rest of this page is about, is that lowering the number is not the same as lowering the risk. The signal is real and worth reading. What you do with it just has to be smarter than "make the number go down."

Homocysteine sits at the center of the methionine cycle. When S-adenosylmethionine, the body's main methyl donor, gives up its methyl group, it is converted through an intermediate into homocysteine ^[1]. From there it has two fates. It can be remethylated back into methionine, a route that depends on folate and vitamin B12, or it can be broken down toward cysteine, a route that depends on vitamin B6. A shortage of any of those vitamins, and impaired kidney function, slows clearance and raises the level in the blood.

This is what makes homocysteine such a useful functional marker: its concentration moves inversely with B-vitamin status, often rising before a standard B12 or folate test looks abnormal ^[1]. A genetic factor matters too. A common variant in the MTHFR gene reduces the activity of an enzyme that supplies the active form of folate, which modestly raises homocysteine, especially when folate intake is low ^[2]. The variant is common enough that it is not, on its own, cause for alarm; its main practical message is to make sure folate intake is adequate.

The association with disease is real and graded. Pooling dozens of studies, a homocysteine about 3 µmol/L lower was associated with roughly 11% lower risk of ischemic heart disease and about 19% lower risk of stroke, with no clear threshold below which the relationship disappears ^[3]. That looked like a clear invitation: lower homocysteine and prevent disease.

The invitation did not pay off the way everyone expected. When large trials gave B vitamins to lower homocysteine, the number fell by about a quarter, but coronary events did not decline at all, and overall mortality was unchanged ^[4]. The most likely explanation is that for heart disease, homocysteine is largely a marker of an underlying problem rather than the problem itself, so lowering it without addressing the cause does little. There was a hint of a modest benefit for stroke, which remains under study. The cognitive picture is more promising: in one randomized trial, lowering homocysteine with B vitamins slowed brain atrophy mainly in people who also had adequate omega-3 status, which suggests the two work together rather than alone ^[5].

So the honest reading is specific. A high homocysteine is a genuine signal, most reliably of a correctable B-vitamin shortfall, and it adds real information about vascular and brain risk. But it is not a number to crush for its own sake. The right move is to find and fix why it is high, usually B vitamins, sometimes kidney or thyroid issues, and to put your actual cardiovascular effort into the markers that respond, like ApoB and the metabolic panel.